MMED (NASDAQ:MMED) Now Covered by Mizuho

Equities researchers at Mizuho initiated coverage on shares of MMED (NASDAQ:MMED) in a research report issued to clients and investors on Tuesday. The firm set an “outperform” rating and a $21.00 price target on the stock. Mizuho’s target price would suggest a potential upside of 46.34% from the company’s previous close.

Several other equities research analysts also recently weighed in on MMED. BTIG Research assumed coverage on MMED in a report on Tuesday. They issued a “buy” rating and a $25.00 price objective for the company. Bank of America began coverage on shares of MMED in a research report on Tuesday. They set a “buy” rating and a $27.00 price objective on the stock. Wall Street Zen raised shares of MMED to a “hold” rating in a report on Saturday, March 14th. Finally, Piper Sandler initiated coverage on MMED in a report on Tuesday. They set a “neutral” rating and a $16.00 price target on the stock. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.33.

MMED Stock Down 0.8%

MMED opened at $14.35 on Tuesday. MMED has a one year low of $14.10 and a one year high of $20.48.

MMED Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.